Kirsten Paulsrud, DPM
Podiatrist · Hutchinson, KSNPI 1063677284
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Smith+Nephew accounts for 68.8% of it on its own, with 10 other manufacturers making up the rest.
Across 58 payments — averaging $42.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$2K
- Stryker$516
- Zyla Life Sciences, Inc.$54
- Titan Surgical Group, LLC$34
- Medtronic$34
- Johnson & Johnson$31
- plus $95 from 5 others
What the payments were for
- Food & beverage$2,442100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 37 | $1,679 |
| Stryker | 9 | $516 |
| Zyla Life Sciences, Inc. | 3 | $54 |
| Titan Surgical Group, LLC | 1 | $34 |
| Medtronic | 2 | $34 |
| Johnson & Johnson | 1 | $31 |
| Polynovo North America LLC | 1 | $26 |
| Heron Therapeutics, Inc. | 1 | $24 |
| Kerecis Limited | 1 | $17 |
| Amgen | 1 | $15 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GRAFIX PL$1,297
- STRAVIX PL$877
- Stravix$274
- BIOFOAM$121
- CROSSCHECK$115
How this compares
$2,442 in reported general payments places this provider in the 70th percentile of 30 podiatrist providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefadroxil | 223 | $2,313 |
| Ammonium Lactate | 68 | $1,504 |
| Gabapentin | 108 | $877 |
| Minocycline Hcl | 52 | $835 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 39 | $443 |
| Terbinafine Hcl | 17 | $248 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $145 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $75 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Hutchinson
- David BlanchoGalena$193K
- Jeffrey RoithOverland Park$69K
- Matthew GallianoOverland Park$19K
- Thomas TruongWichita$11K
- Jennifer PhillipsOverland Park$3K
- Nhi leLenexa$3K
- Henry GoppertTopeka$3K
- Nicholas PosgeEl Dorado$3K
- Frank GalbraithWichita$2K
- Rebecca JohnsonSalina$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.